Journal of the Serbian Chemical Society
JSCS-info@shd.org.rs • www.shd.org.rs/JSCS

ACCEPTED MANUSCRIPT

This is an early electronic version of an as-received manuscript that hasbeen accepted for publication in the Journal of the Serbian Chemical Society but has not yet been subjected to the editing process and publishing procedure applied by the JSCS Editorial Office.

Please cite this article as M. D. Altintop, H. E. Temel, A. Özdemir, *J. Serb. Chem. Soc.* (2022) https://doi.org/10.2298/JSC220907001A

This "raw" version of the manuscript is being provided to the authors and readers for their technical service. It must be stressed that the manuscript still has to be subjected to copyediting, typesetting, English grammar and syntax corrections, professional editing and authors' review of the galley proof before it is published in its final form. Please note that during these publishing processes, many errors may emerge which could affect the final content of the manuscript and all legal disclaimers applied according to the policies of the Journal.

Journal of the Serbian Chemical Society
JSCS-info@shd.org.rs • www.shd.org.rs/JSCS
J. Serb. Chem. Soc. **00(0)** 1-11 (2023)
JSCS–12058
Original scientific paper
Published DD MM, 2022

Accepted Manuscript

Microwave-assisted synthesis of a series of 4,5-dihydro-1*H*-pyrazoles endowed with selective COX-1 inhibitory potency

MEHLİKA DİLEK ALTINTOP[1], HALİDE EDİP TEMEL[2] and AHMET ÖZDEMİR[1]*

[1]*Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Anadolu University, 26470 Eskişehir, Turkey and* [2]*Department of Biochemistry, Faculty of Pharmacy, Anadolu University, 26470 Eskişehir, Turkey*

(Received 7 September; Revised 22 November; Accepted 30 December 2022)

Abstract: More efforts have been directed towards the discovery of selective COX-1 inhibitors due to recent works highlighting the involvement of COX-1 in the pathogenesis of pain, neuroinflammation, cancer and cardiovascular disorders. In this context, this paper aims to describe 2-pyrazolines endowed with selective COX-1 inhibitory potency. An efficient microwave-assisted protocol was applied for the preparation of a series of pyrazolines, which were tested for their COX-1 and COX-2 inhibitory effects using a colorimetric assay. The cytotoxic properties of the most potent derivatives on NIH/3T3 fibroblast cells were determined using MTT method. 1-(3-Fluorophenyl)-5-(3,4-methylendioxyphenyl)-3-(2-thienyl)-4,5-dihydro-1*H*-pyrazole (**2g**) and 1-(3-bromophenyl)-5-(3,4-methylendioxyphenyl)-3-(2-thienyl)-4,5-dihydro-1*H*-pyrazole (**2h**) were determined as selective COX-1 inhibitors. According to the *in silico* data obtained from Schrödinger's QikProp module, both compounds are estimated to possess favorable oral bioavailability and drug-likeness. This work could be a rational guideline for further modifications at different sites on 2-pyrazoline motif to bring out a new class of selective COX-1 inhibitors.

Keywords: pyrazoline; microwave heating; cyclooxygenase-1 inhibition

INTRODUCTION

Prostanoids (prostaglandins (PGs), thromboxane and prostacyclin) belong to the eicosanoid family of lipid mediators generated from arachidonic acid (AA).[1,2] Prostanoids play a central role in numerous physiological (*e.g.* gastrointestinal (GI) integrity) and pathological (*e.g.* inflammation) processes.[2,3]

Cyclooxygenase (COX) is a rate-limiting enzyme implicated in the conversion of AA into prostanoids. There are two COX isozymes, namely the constitutive COX-1 and the inducible COX-2.[2] Both COXs possess similar structures, catalytic features, and subcellular localizations[2] and yield the same product, prostaglandin H_2.

*Corresponding author E-mail: ahmeto@anadolu.edu.tr
https://doi.org/10.2298/JSC220907001A

However, COX isozymes differ in terms of expression, tissue distribution, and biological tasks.[4] COX-1 contributes to homeostasis in most tissues (*e.g.* platelets, GI tract, kidney, brain, lung, liver and spleen) where it is expressed under normal physiological conditions for the synthesis of PGs and exerts cytoprotective action along with the regulation of platelet activity, gastric and renal functions.[4,5] In general, non-steroidal anti-inflammatory drugs (NSAIDs), which inhibit both COX isoforms, cause GI damage through COX-1 inhibition.[6] In order to avoid GI toxicity, many researchers have focused on the discovery of selective COX-2 inhibitors based on the hypothesis that PGs beneficial for GI protection were generated solely by means of COX-1 activity, whilst PGs responsible for inflammation and pain were produced exclusively through COX-2 activity.[6,7] However, this assumption has lost its actuality since it is understood that COX-2 is constitutively expressed in some tissues and COX-1-derived PGs are also involved in inflammation and therefore COX-1 sparing is not adequate to prevent GI toxicity.[7,8]

Recent studies have revealed that COX-1 participates in the pathogenesis of many diseases (*e.g.* cancer, neuroinflammation, cardiovascular diseases and pain).[4,9] It is noteworthy that low-dose aspirin is beneficial in the prevention of cardio-vascular disorders through the inhibition of platelet COX-1. In addition, mounting evidence has also shown that long-term use of aspirin reduces the risk of some types of cancer and other diseases such as Alzheimer's disease.[9]

Despite all efforts devoted to the discovery of selective COX-1 inhibitors, there is only one selective COX-1 inhibitor (mofezolac) currently prescribed as a NSAID just in Japan for the management of pain / inflammation after surgery, trauma, or tooth extraction; lumbago, cervicobrachial syndrome and scapulohumeral periarthritis.[9,10] SC-560 and FR122047, selective COX-1 inhibitors commonly utilized as reference agents in experimental studies, could not be introduced to the market as therapeutic agents because of their pharmacodynamic and pharmacokinetic drawbacks.[6,9]

From a chemical structural point of view, selective COX 1 inhibitors (mofe-zolac, SC-560, and FR122047) (Fig. 1) possess a five-membered heteroaromatic central ring in common (isoxazole in mofezolac, pyrazole in SC-560, and thiazole in FR122047). Moreover, two aromatic rings linked to adjacent atoms of the five-membered heteroaromatic nucleus are found to be determinant.[6,9]



Mofezolac SC-560 FR122047

Figure 1. Selective COX-1 inhibitors

Accepted Manuscript

2-Pyrazoline (4,5-dihydro-1*H*-pyrazole), the partially reduced form of pyrazole, is a privileged member of the nitrogen-containing heterocycles due to its indispensable role in the discovery of new therapeutic drugs with improved potency and less toxicity along with favorable pharmacokinetic profiles.[11,12] 2-pyrazolines have been reported to possess a broad range of biological activities (analgesic, anti-inflammatory, antitumor, antidepressant, antimicrobial, *etc.*) attributable to their ability to interact with pivotal biological targets involved in diverse biochemical pathways.[11-27] There are many pyrazoline-based marketed agents as well as therapeutic candidates undergoing preclinical and clinical trials.[12] Some of them exert potent analgesic and anti-inflammatory action through the inhibition of COXs. Phenazone was the first pyrazoline-based agent used for the management of pain and inflammation. Dipyrone (metamizole) (Fig. 2), was introduced to the market nearly a century ago and it is still used an analgesic and antipyretic drug in many countries worldwide.[27]



Figure 2. Dipyrone

A vast number of scientific reports related to 2-pyrazolines exerting marked COX inhibitory potency[17-27] prompted us to design a series of pyrazoline-based selective COX-1 inhibitors. In this context, the microwave (MW)-assisted synthesis of eight 2-pyrazolines was carried out expeditiously and *in vitro* experiments were performed to evaluate their potency as selective COX-1 inhibitors.

EXPERIMENTAL

General procedure

The chemicals used without further purification were obtained from commercial vendors (Sigma-Aldrich (St. Louis, MO, USA), Merck (Darmstadt, Germany), Acros Organics (Geel, Belgium), and Alfa Aesar (Karlsruhe, Germany). The reactions were performed in Monowave 400 MW Reactor (Anton Paar, Graz, Austria) in sealed reaction vessels, power supply voltage: AC 230 V (±10 %), 50 Hz/60 Hz, installed microwave power: 850 W, power consumption: 1600 VA, operating frequency: 2455 MHz. compressed air cooling: 5.5 to 6 bar (80 to 87 psi). The reaction conditions are optimized by changing temperature and time under solvent medium. Melting points (M.P.) were detected by means of a digital melting point apparatus (Electrothermal, Staffordshire, UK) and are uncorrected. Thin Layer Chromatography (TLC) was performed on TLC Silica gel 60 F_{254} aluminium sheets (Merck, Darmstadt, Germany) using petroleum ether-ethyl acetate solvent systems (3:1 and 1:1). IR spectra were recorded on a Fourier Transform IR spectrophotometer (Shimadzu, Tokyo, Japan). ^{1}H and ^{3}C NMR spectra

Accepted Manuscript

were acquired using a NMR spectrometer (at 300 and 75 MHz, respectively) (Bruker, Billerica, MA, USA). Chemical shifts were expressed in parts per million (ppm). HRMS spectra were recorded on a LCMS-IT-TOF system (Shimadzu, Kyoto, Japan). The spectral data of the compounds were given in Supplementary material.

Synthetic procedures

General procedure for the preparation of 1-(2-thienyl)-3-(3,4-methylenedioxyphenyl)-2-propen-1-one (**1**)

2-Acetylthiophene (0.02 mol) was reacted with piperonal (0.02 mol) in the presence of 40 % aqueous NaOH (5 mL) in absolute ethanol (30 mL) at room temperature (rt) for 24 h. Upon completion of the reaction, the reaction mixture was poured into crushed ice. The precipitate was filtered, and washed with water. After drying, the product was crystallized from ethanol.[28]

General procedure for the preparation of 1-aryl-3-(2-thienyl)-5-(3,4-methylenedioxyphenyl)-2-pyrazolines (**2a-h**)

A mixture of compound **1** (1 mmol) and arylhydrazine hydrochloride (1.5 mmol) in absolute ethanol (8 mL) was heated to 180 °C within 15 minutes and kept at this temperature for 18 minutes under MW irradiation in a reaction vial with magnetic stirring at 500 rpm in a Monowave 400 MW Reactor equipped with a ruby thermometer. Upon the completion of the reaction, the reaction mixture was cooled to rt. The precipitate was collected by filtration and dried. The product was crystallized from ethanol.

Biochemistry

Determination of COX inhibitory activity

COX inhibitor screening assay (catalog no: 701050) was performed to determine the inhibitory activities of compounds **2a-h** (at 100 µM) towards COX-1 and COX-2 according to the manufacturer's guideline (Cayman, Ann Arbor, MI, USA). All measurements were performed in triplicate and the results were expressed as mean ± SD. SC-560 (at 1 µM) was used as a selective COX-1 inhibitor, whereas rofecoxib (at 10 µM) was used as a selective COX-2 inhibitor.

Cell culture and drug treatment

NIH/3T3 mouse embriyonic fibroblast cells (ATCC® CRL-1658™) were cultured and drug treatments were performed as reported previously.[29]

MTT test

The level of cellular MTT (Sigma - Aldrich, St. Louis, MO, USA) reduction was quantified as explained earlier [30] with minor modifications.[29]

In silico pharmacokinetic studies

QikProp, an *in silico* ADME module within the Maestro suite produced by Schrödinger (Schrödinger Release 2022-2, LLC, New York, USA), was used to predict the crucial physicochemical parameters of compounds **2g** and **2h** for the assessment of their absorption, distribution, metabolism, elimination (ADME) profiles.

RESULTS AND DISCUSSION

Chemistry

The preparation of 2-pyrazolines (**2a-h**) followed the general pathway depicted in Scheme 1. The chalcone (**1**) was obtained *via* the Claisen-Schmidt condensation of 2-acetylthiophene with piperonal.

Accepted Manuscript



Scheme 1. The synthetic route for the preparation of compounds **2a-h**. Reagents and conditions: (i) Piperonal, 40% (w/v) NaOH, absolute ethanol, rt, 24 h; (ii) Arylhydrazine hydrochloride, absolute ethanol, MW, 180 °C, 18 min.

MW-assisted synthesis is recognized as an advantageous and eco-friendly technique for the rapid and efficient preparation of heterocyclic compounds including nitrogen-containing heterocycles.[31-33] The employment of this technique in dedicated MW reactors provides efficient and controlled heating along with excellent parameter control and therefore MW heating has several advantages over conventional heating such as shortening reaction time and obtaining products with high purity and yield.[31-35] In this work, an efficient MW-assisted protocol was applied for the preparation of compounds **2a-h**. Compounds **2a**, **2b**, **2c**, **2d** and **2e** were previously synthesized by our research group using a conventional method.[28] The comparison between MW and conventional techniques was made by comparing yield and total reaction time (Table I). MW technique led to a reduction in reaction time (from 480 min to 18 min) and an increase in product yields.

TABLE I. MW technique vs conventional method for the preparation of the compounds



Compound	R	MW Irradiation		Conventional*	
		Yield, %	Time, min	Yield, %	Time, min
2a	4-CN	95	18	93	480
2b	4-F	82	18	76	480
2c	4-Br	91	18	90	480
2d	4-CH_3	73	18	47	480
2e	4-SO_2CH_3	94	18	63	480
2f	3-NO_2	84	18	-	-
2g	3-F	81	18	-	-
2h	3-Br	80	18	-	-

***Compounds **2a-e** were previously synthesized by our research team using a conventional method.[28] Compounds **2f**, **2g** and **2h** are reported for the first time in this work.

Accepted Manuscript

The structures of compounds **2a-h** were confirmed by infrared (IR), nuclear magnetic resonance (NMR, ^{1}H and ^{13}C), and High resolution mass spectrometry (HRMS).

In the IR spectra of compounds **2a-h**, the absence of a band at 1643.55 cm^{-1} due to the C=O stretching [28] confirmed that the formation of the 2-pyrazoline scaffold occurred efficiently. The C=N, C=C and C-N stretching bands appeared in the region 1612-1419 and 1396-1107 cm^{-1}, respectively. In the ^{1}H NMR spectra of compounds **2a-h**, the CH_2 protons of the 2-pyrazoline scaffold resonated as a pair of doublet of doublets at 3.08-3.26 ppm (C_4-H_A) (J_{AB} = 17.28 to 17.64 Hz, J_{AX} = 4.95-6.81 Hz) and 3.84-4.00 ppm (C_4-H_B) (J_{BA} = 17.25-17.70 Hz, J_{BX} = 11.91 to 12.06 Hz) (Fig. 3).



2a-h

R= 4-CN, 4-F, 4-Br, 4-CH_3, 4-SO_2CH_3, 3-NO_2, 3-F, 3-Br

Figure 3. The ABX system of the pyrazoline scaffold belonging to compounds **2a-h**

The CH proton appeared as a doublet of doublets at 5.36-5.63 ppm (C_5-H_X) (J_{BX} = 11.85-12.06 Hz, J_{AX} = 4.95-6.81 Hz). The O-CH_2-O protons gave rise to a singlet or a doublet in the region 5.97-6.04 ppm. The ^{13}C NMR chemical shift values of the carbons at 44.14-44.63 ppm (C4), 62.53-64.11 ppm (C5) and 144.46 to 154.85 ppm (C3) supported the ^{1}H NMR data confirming the formation of the pyrazoline motif. The HRMS data of compounds **2a-h** were also consistent with other spectral data.

Biochemistry

A colorimetric test was conducted to assess the inhibitory effects of compounds **2a-h** on COX-1 and COX-2 (Table II). Among compounds **2a-h**, compounds **2g** and **2h** were found to selective COX-1 inhibitors as compared to SC-560. The inhibition of compounds **2g** and **2h** at 100 µM for COX-1 were found as 50.92±2.80 and 57.70±2.64 %, respectively as compared to SC-560 (97.36± ±2.62 % at 1 µM), a selective COX-1 inhibitor. *m*-Fluoro and *m*-bromo substituents enhanced COX-1 inhibitory potency.

Accepted Manuscript

TABLE II. The inhibitory effects of compounds **2a-h**, SC-560 and rofecoxib on COXs

Compound (100 µM)	Inhibition, %	
	COX-1	COX-2
2a	----	----
2b	----	----
2c	----	26.30±3.46
2d	9.65±1.56	----
2e	----	----
2f	----	36.48±2.18
2g	50.92±2.80	----
2h	57.70±2.64	----
SC-560 (1 µM)	97.36±2.62	----
Rofecoxib (10 µM)	----	98.36±1.86

The replacement of the halogen atom with the nitro group (compound **2f**) led to the loss of COX-1 inhibitory potency. However, *m*-nitro substitution gave rise to selective COX-2 inhibitory activity (36.48±2.18 %). *p*-fluoro substitution (compound **2b**) caused the loss of inhibitory potency towards both COXs, whereas *p*-bromo substitution (compound **2c**) resulted in selective COX-2 inhibitory potency (26.30±3.46 %). The inhibition of compounds **2c** and **2f** at 100 µM were detected as 26.30±3.46 and 36.48±2.18 %, respectively in comparison with rofecoxib (98.36±1.86 % at 10 µM), a selective COX-2 inhibitor. Compounds **2a**, **2b** and **2e** did not show any inhibitory activity towards COXs. According to the results, *p*-cyano, *p*-fluoro and *p*-methylsulfonyl groups led to the loss of COX inhibitory activity.

Compounds **2g** and **2h**, the most potent COX-1 inhibitors in this series, were subjected to MTT assay for the evaluation of their cytotoxicity towards NIH/3T3 (normal) cells. Both compounds did not exhibit any cytotoxicity towards NIH/3T3 cell line at the tested concentrations (IC_{50} > 500 µM).

In silico ADME prediction

In silico approaches are frequently used to assess pharmacokinetic profiles of drug candidates in drug development process since ADME experiments are not only costly and time-consuming for a vast number of chemicals, but also require a large number of animal tests and, correspondingly ethical procedures.[36] In this context, a computational study for the prediction of the pharmacokinetic features of compounds **2g** and **2h** was performed (Table III). The predicted values for total solvent accessible surface area (SASA), Van der Waals surface area of polar nitrogen and oxygen atoms (PSA), octanol/water partition coefficient (QPlogPo/w) and binding to human serum albumin (QPlogKhsa) values were detected within the optimum range.

The predicted apparent Caco-2 cell permeability (QPPCaco) values of compounds **2g** and **2h** were found to be higher than 500 and therefore both compounds are estimated to possess good intestinal permeability. Compounds **2g** and **2h** are also

Accepted Manuscript

predicted to possess 100.000 % human oral absorption. Furthermore, both compounds violated only one parameter of Lipinski's and Jorgensen's rules, making them drug-like molecules endowed with favorable oral bioavailability.

TABLE III. Predicted pharmacokinetic features of compounds **2g** and **2h**

Property or descriptor	Compound **2g**	Compound **2h**	Range or recommended values
SASA	589.893	605.657	300.0 – 1000.0
PSA	32.674	32.687	7.0 – 200.0
QPlogPo/w	5.704	6.041	–2.0 – 6.5
QPPCaco	8585.887	8883.859	<25 poor, >500 great
QPlogBB	0.730	0.813	–3.0 – 1.2
QPPMDCK	10000.000	10000.000	<25 poor, >500 great
QPlogKhsa	1.009	1.112	–1.5 – 1.5
Human Oral Absorption%	100.000	100.000	>80% is high, <25% is poor
Rule of Five*	1	1	maximum is 4
Rule of Three**	1	1	maximum is 3

*Rule of Five: Number of violations of Lipinski's rule of five. The rules are: molecular weight of the molecule < 500, QPlogPo/w <5, hydrogen-bond donor atoms ≤ 5, hydrogen-bond acceptor atoms ≤ 10. Compounds that provide these rules are considered as drug-like molecules. **Rule of Three: Number of violations of Jorgensen's rule of three. The three rules are: predicted aqueous solubility (QPlogS) > -5.7, QPPCaco > 22 nm s^{-1}, # Primary Metabolites < 7. Compounds with fewer (and preferably no) violations of these rules are more likely to be orally available agents.[37]

The capability of a drug to penetrate the blood-brain barrier (BBB) is required for its use in the treatment of central nervous system (CNS) disorders.[38,39] Predicted brain/blood partition coefficient (QPlogBB) was used to estimate the BBB permeability of each compound. The QPlogBB values of both compounds were detected within the recommended values. Moreover, Madin-Darby canine kidney (MDCK) cell permeability is an additional criterion which is widely used for the assessment of BBB penetration.[40,41] The estimated apparent MDCK cell permeability (QPPMDCK) values of both compounds were found to be higher than 500. Based on the *in silico* data, compounds **2g** and **2h** are predicted to possess the ability to cross BBB.

CONCLUSION

In this paper, we conducted an efficient MW-assisted protocol for the preparation of a series of pyrazolines (**2a-h**), which were investigated for their inhibitory effects on COXs at 100 µM using an *in vitro* colorimetric assay. According to *in vitro* experimental data, compounds **2g** and **2h** were determined as selective COX-1 inhibitors in this series as compared to SC-560. MTT test was applied to assess their cytotoxic effects on NIH/3T3 cells. Both compounds did not display any cytotoxicity towards NIH/3T3 cell line at the tested concentrations. *In silico* ADME prediction was performed for the assessment of their pharmacokinetic features. Compounds **2g** and **2h** are predicted to have favorable

Accepted Manuscript

oral bioavailability and drug-likeness. In the view of this work, a new generation of pyrazolines could be designed through the molecular modification of compounds **2g** and **2h** for the management of many diseases in which selective COX-1 inhibition is required.

SUPPLEMENTARY MATERIAL

Full experimental details for compounds **2a-h** reported in this work are provided in Supplementary Material (https://www.shd-pub.org.rs/index.php/JSCS/article/view/12058), with spectroscopic data, including IR, ^{1}H NMR, ^{13}C NMR, and HRMS data.

ИЗВОД

Синтеза под дејством микроталса серије деривата 4,5-дихидро-1*H*-питазола који поседују изражену инхибиторну активност према COX-1

MEHLIKA DILEK ALTINTOP[1], HALIDE EDIP TEMEL[2] и AHMET ÖZDEMIR[1]

[1]Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Anadolu University, 26470 Eskişehir, Turkey и [2]Department of Biochemistry, Faculty of Pharmacy, Anadolu University, 26470 Eskişehir, Turkey

Учињен је значајан покушају проналажењу селективних COX-1 инхибитора током скоријих истраживања о значају COX-1у патогенези бола, упале неурона, канцеру, и кардиоваскуларним поремећајима. У том правцу, у овом раду описани су деривати 2-пиразолина који поседују способност селективне инхибиције COX-1. Примењен је ефикасан протокол употребом микро-таласа за добијање серије пиразолина који су тестирани као инхибитори COX-1и COX-2 применом колориметријског есеја. Цитотоксична активност најактивнијих деривата је одређена на NIH/3T3 ћелијам фибропласта применом MTT метода. Показано је да су деривати 1-(3-флуорфенил)-5-(3,4-метиледиоксифенил)-3-(2-тиенил)-4,5-дихидро-1H-пиразол (***2g***) и 1-(3-бромфенил)-5-(3,4-метиледиоксифенил)-3-(2-тиенил)-4,5-дихидро-1H-пиразол (**2h**) селективни COX-1 инхибитори. На основу података добијених in silico прорачунима помоћу Schrödinger QikProp модула, процењено је да оба једињења имају повољну оралну биодоступност и повољне drug-likeness особине. Овај рад би могао да буде рационалан водич за даље модификације на различитим позицијама 2-пиразолинског језгра до нове класе селективних COX-1 инхибитора.

(Примљено 7. септембра; ревидирано 22. новембра; прихваћено 30. децембра 2022.)

REFERENCES

1. T. Schmid, B. Brüne *Front. Immunol.* **12** (2021) 714042 (https://dx.doi.org/10.3389/fimmu.2021.714042)
2. L. L. Mazaleuskaya, E. Ricciotti, *Adv. Exp. Med. Biol.* **1274** (2020) 29 (https://dx.doi.org/10.1007/978-3-030-50621-6_3)
3. C. S. Williams, M. Mann, R. N. DuBois, *Oncogene* **18** (1999) 7908 (https://dx.doi.org/10.1038/sj.onc.1203286)
4. A. Pannunzio, M. Coluccia, *Pharmaceuticals* **11** (2018) 101 (https://dx.doi.org/10.3390/ph11040101)
5. V. Sharma, P. Bhatia, O. Alam, M. Javed Naim, F. Nawaz, A. Ahmad Sheikh, M. Jha *Bioorg. Chem.* **89** (2019) 103007 (https://dx.doi.org/10.1016/j.bioorg.2019.103007)
6. M. G. Perrone, A. Scilimati, L. Simone, P. Vitale, *Curr. Med. Chem.***17** (2010) 3769 (https://dx.doi.org/10.2174/092986710793205408)

Accepted manuscript

7. E. Caiazzo, A. Ialenti, L. Cicala, C. Vitale, *Eur. J. Pharmacol.* **848** (2019) 105 (https://dx.doi.org/10.1016/j.ejphar.2019.01.044)
8. P. Vitale, A. Panella, A. Scilimati, M. G. Perrone, *Med. Res. Rev*. **36** (2016) 641 (https://dx.doi.org/10.1002/med.21389)
9. P. Vitale, A. Scilimati, M. G. Perrone, *Curr. Med. Chem.* **22** (2015) 4271 (https://dx.doi.org/10.2174/0929867322666151029104717)
10. K. Goto, H. Ochi, Y. Yasunaga, H. Matsuyuki, T. Imayoshi, H. Kusuhara, T. Okumoto, *Prostaglandins Other Lipid Mediat.***56** (1998) 245 (https://dx.doi.org/10.1016/s0090-6980(98)00054-9)
11. J.M. Alex, R. Kumar, *J. Enzyme Inhib. Med. Chem*. **29** (2014) 427 (https://dx.doi.org/10.3109/14756366.2013.795956)
12. B. Nehra, S. Rulhania, S. Jaswal, B. Kumar, G. Singh, V. Monga, *Eur. J. Med. Chem.* **205** (2020) 112666 (https://dx.doi.org/10.1016/j.ejmech.2020.112666)
13. S. Kumar, S. Bawa, S. Drabu, R. Kumar, H. Gupta, *Recent Pat. Anti-Infect. Drug Discov*. **4** (2009) 154 (https://dx.doi.org/10.2174/157489109789318569)
14. M. R. Shaaban, A. S. Mayhoub, A. M. Farag, *Expert Opin. Ther. Pat.* **22** (2012), 253 (https://dx.doi.org/10.1517/13543776.2012.667403)
15. A. Marella, R. Ali, T. Alam, R. Saha, O. Tanwar, M. Akhter, M. Shaquiquzzaman, M. M. *Mini-Rev. Med. Chem.* **13** (2013) 921 (https://dx.doi.org/10.2174/1389557511313060012)
16. D. Matiadis, M. Sagnou, *Int. J. Mol. Sci*. **21** (2020) 5507 (https://dx.doi.org/10.3390/ijms21155507)
17. C. Cusan, G. Spalluto, M. Prato, M. Adams, A. Bodensieck, R. Bauer, A. Tubaro, P. Bernardi, T. Da Ros, *Il Farmaco* **60** (2005) 327 (https://dx.doi.org/10.1016/J.FARMAC.2004.09.002)
18. M. V. R. Reddy, V. K. Billa, V. R. Pallela, M. R. Mallireddigari, R. Boominathan, J.L. Gabriel, E. P. Reddy, *Bioorg. Med. Chem*. **16** (2008) 3907 (https://dx.doi.org/10.1016/j.bmc.2008.01.047)
19. R. Fioravanti, A. Bolasco, F. Manna, F. Rossi, F. Orallo, F. Ortuso, S. Alcaro, R. Cirilli, *Eur. J. Med. Chem*. **45** (2010) 6135 (https://dx.doi.org/10.1016/j.ejmech.2010.10.005)
20. S. Carradori, D. Secci, A. Bolasco, C. De Monte, M. Yáñez, *Arch. Pharm. Chem. Life Sci*. **345** (2012) 973 (https://dx.doi.org/10.1002/ardp.201200249)
21. M. A. El-Sayed, N. I. Abdel-Aziz, A. A. Abdel-Aziz, A. S. El-Azab, K. E. ElTahir, *Bioorg. Med. Chem*. **20** (2012) 3306 (https://dx.doi.org/10.1016/j.bmc.2012.03.044)
22. M. Yu, H. Yang, K. Wu, Y. Ji, L. Ju, X. Lu, *Bioorg. Med. Chem*. **22** (2014) 4109 (https://dx.doi.org/10.1016/j.bmc.2014.05.059)
23. K. R. A. Abdellatif, M. A. Abdelgawad, M. B. Labib, T. H. Zidan, *Bioorg. Med. Chem. Lett*. **25** (2015) 5787 (https://dx.doi.org/10.1016/j.bmcl.2015.10.047)
24. K. R. A. Abdellatif, H. A. H. Elshemy, A. A. Azoz, *Bioorg. Chem*. **63** (2015) 13 (https://dx.doi.org/10.1016/j.bioorg.2015.09.002)
25. M. A. Abdel-Sayed, S. M. Bayomi, M. A. El-Sherbeny, N. I. Abdel-Aziz, K. E. ElTahir, G. S. Shehatou, A. A. Abdel-Aziz, *Bioorg. Med. Chem*. **24** (2016) 2032 (https://dx.doi.org/10.1016/j.bmc.2016.03.032)
26. K. R. A. Abdellatif, M. T. Elsaady, S. A. Abdel-Aziz, A. H. Abusabaa, *J. Enzyme Inhib. Med. Chem*. **31** (2016) 1545 (https://dx.doi.org/10.3109/14756366.2016.1158168)
27. M. Lutz, *J. Clin. Pharmacol*. **59** (2019) 1433 (https://dx.doi.org/10.1002/jcph.1512)
28. A. Özdemir, B. Sever, M. D. Altıntop, E. Kaya Tilki, M. Dikmen, *Molecules* **23** (2018) 2151 (https://dx.doi.org/10.3390/molecules23092151)

Accepted Manuscript

29. A. Özdemir, M. D. Altıntop, Z. A. Kaplancıklı, G. Turan-Zitouni, G. Akalın Çiftçi, Ş. Ulusoylar Yıldırım, *J. Enzyme Inhib. Med. Chem*. **28** (2013) 1221 (https://dx.doi.org/10.3109/14756366.2012.724682)
30. T. Mosmann, *J. Immunol. Methods* **16** (1983) 55 (https://dx.doi.org/10.1016/0022-1759(83)90303-4)
31. E. Berrino, C. T. Supuran, *Expert Opin. Drug Discov.* **13** (2018) 861 (https://dx.doi.org/10.1080/17460441.2018.1494721)
32. T. L. Lambat, P. K. P. G. Chopra, S. H. Mahmood, *Curr. Org. Chem*. **24** (2020) 2527 (https://dx.doi.org/10.2174/1385272824999200622114919)
33. M. Henary, C. Kananda, L. Rotolo, B. Savino, E. A. Owens, G. Cravotto, *RSC Adv.* **10** (2020) 14170 (https://dx.doi.org/10.1039/D0RA01378A)
34. M. B. Gawande, S. N. Shelke, R. Zboril, R. S. Varma, *Acc. Chem. Res.* **47** (2014) 1338 (https://dx.doi.org/10.1021/ar400309b)
35. J. M. Kremsner, A. Stadler, *A Chemist's Guide to Microwave Synthesis*, 3rd ed.; Anton Paar GmbH: Graz, Austria, 2018, p. 300
36. Y. Wang, J. Xing, Y. Xu, N. Zhou, J. Peng, Z. Xiong, X. Liu, X. Luo, C. Luo, K. Chen, M. Zheng, H. Jiang, *Q. Rev. Biophys*. **48** (2015) 488 (https://dx.doi.org/10.1017/S0033583515000190)
37. Schrödinger Release 2022-2: Schrödinger, LLC, New York, NY, USA (https://www.schrodinger.com/)
38. C. Lohmann, S. Hüwel, H. J. Galla, *J. Drug Target*. **10** (2002) 263 (https://dx.doi.org/10.1080/10611860290031903)
39. T. J. Hou, X. J. Xu, *J. Chem. Inf. Comput. Sci*. **43** (2003) 2137 (https://dx.doi.org/10.1021/ci034134i)
40. S. Shahbazi, T. R. Sahrawat, M. Ray, S. Dash, D. Kar, S. Singh, *PLoS ONE* **11** (2016) e0156156 (https://dx.doi.org/10.1371/journal.pone.0156156)
41. F. Neumaier, B. D. Zlatopolskiy, B. Neumaier, *Pharmaceutics* **13** (2021) 1542 (https://dx.doi.org/10.3390/pharmaceutics13101542).

Accepted Manuscript

Accepted Manuscript

Journal of the Serbian Chemical Society
JSCS-info@shd.org.rs • www.shd.org.rs/JSCS
J. Serb. Chem. Soc. **00(0)** S1-S19 (2023) *Supplementary material*

SUPPLEMENTARY MATERIAL TO

Microwave-assisted synthesis of a series of 4,5-dihydro-1*H*-pyrazoles endowed with selective COX-1 inhibitory potency

MEHLİKA DİLEK ALTINTOP[1], HALİDE EDİP TEMEL[2] and AHMET ÖZDEMİR[1]*

[1]*Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Anadolu University, 26470 Eskişehir, Turkey and* [2]*Department of Biochemistry, Faculty of Pharmacy, Anadolu University, 26470 Eskişehir, Turkey*

*1-(4-Cyanophenyl)-5-(3,4-methylenedioxyphenyl)-3-(2-thienyl)-4,5-dihydro-1H-pyrazole (**2a**)*[28]

Beige powder. M.P.: 156-158 ºC. IR ν_{max} (cm^{-1}): 3103, 3076, 2976, 2899, 2208, 1600, 1521, 1510, 1481, 1440, 1396, 1325, 1311, 1242, 1193, 1174, 1151, 1132, 1118, 1095, 1056, 1035, 993, 958, 933, 900, 860, 840, 821, 802, 734, 727, 665. ^{1}H NMR (300 MHz, DMSO-d_6) δ / ppm: 3.26 (dd, J_{AB} = 17.64 Hz, J_{AX} = 4.95 Hz, 1H, C_4-H_A pyrazoline), 4.00 (dd, J_{BA} = 17.70 Hz, J_{BX} = 11.97 Hz, 1H, C_4-H_B pyrazoline), 5.63 (dd, J_{BX} = 11.85 Hz, J_{AX} = 4.95 Hz, 1H, C_5-H_X pyrazoline), 6.04 (d, J = 2.40 Hz, 2H), 6.78-6.81 (m, 2H), 6.93 (d, J = 7.92 Hz, 1H), 7.07 (d, J = 8.82 Hz, 2H), 7.18-7.21 (m, 1H), 7.42 (d, J = 3.57 Hz, 1H), 7.63 (d, J = 8.85 Hz, 2H), 7.74-7.76 (m, 1H). ^{13}C NMR (75 MHz, DMSO-d_6) δ / ppm: 44.3 (CH_2), 62.5 (CH), 99.5 (C), 101.6 (CH_2), 106.4 (CH), 109.2 (CH), 113.2 (2CH), 119.4 (CH), 120.4 (C), 128.5 (CH), 129.2 (CH), 129.5 (CH), 133.8 (2CH), 135.4 (d, J = 17.26 Hz, 2C), 146.8 (C), 147.2 (C), 147.5 (C), 148.3 (C). HRMS (*m/z*): $[M+H]^+$ calcd. for $C_{21}H_{15}N_3O_2S$: 374.0958. Found: 374.0964.

*1-(4-Fluorophenyl)-5-(3,4-methylenedioxyphenyl)-3-(2-thienyl)-4,5-dihydro-1H-pyrazole (**2b**)*[28]

Brown powder. M.P.: 138-139 ºC. IR ν_{max} (cm^{-1}): 3082, 2960, 2885, 1604, 1504, 1496, 1481, 1442, 1373, 1361, 1315, 1288, 1247, 1224, 1180, 1153, 1109, 1078, 1033, 993, 927, 910, 866, 813, 802, 746, 707, 661. ^{1}H NMR (300 MHz, DMSO-d_6) δ / ppm: 3.17 (dd, J_{AB} = 17.31 Hz, J_{AX} = 6.81 Hz, 1H, C_4-H_A pyrazoline), 3.93 (dd, J_{BA} = 17.31 Hz, J_{BX} = 11.94 Hz, 1H, C_4-H_B pyrazoline), 5.42 (dd, J_{BX} = 11.94 Hz, J_{AX}= 6.81 Hz, 1H, C_5-H_X pyrazoline), 6.04 (s, 2H), 6.83-6.86 (m, 2H), 6.94-6.97 (m, 1H), 6.98-7.00 (m, 2H), 7.05-7.11 (m, 2H), 7.14-7.17 (m, 1H), 7.31 (d, J = 3.48 Hz, 1H), 7.66 (d, J= 4.98 Hz, 1H). ^{13}C NMR (75 MHz, DMSO-d_6) δ / ppm: 44.4 (CH_2), 64.1 (CH), 101.6 (CH_2), 106.6 (CH), 109.1 (CH), 114.7 (d, J = 7.49 Hz, 2CH), 115.9 (d, J = 22.18 Hz, 2CH), 119.7 (CH), 123.2 (C), 128.1 (d, J= 22.19 Hz, 2CH), 136.2 (d, J= 20.52 Hz, CH), 141.5 (C), 144.5 (C), 147.1 (C), 148.2 (C), 154.9 (C), 157.9 (C). HRMS (*m/z*): $[M+H]^+$ calcd. for $C_{20}H_{15}FN_2O_2S$: 367.0911. Found: 367.0917.

*Corresponding author E-mail: ahmeto@anadolu.edu.tr

Accepted Manuscript

*1-(4-Bromophenyl)-5-(3,4-methylenedioxyphenyl)-3-(2-thienyl)-4,5-dihydro-1H-pyrazole (**2c**)*[28]

Dark beige powder. M.P.: 107-108 ºC. IR ν_{max} (cm^{-1}): 3105, 3070, 2962, 2899, 1589, 1481, 1442, 1381, 1319, 1240, 1193, 1128, 1118, 1107, 1093, 1072, 1035, 997, 958, 937, 898, 854, 813, 802, 748, 721, 705, 690. ^{1}H NMR (300 MHz, DMSO-d_6) δ / ppm: 3.18 (dd, J_{AB}= 17.43 Hz, J_{AX}= 6.21 Hz, 1H, C_4-H_A pyrazoline), 3.94 (dd, J_{BA}= 17.25 Hz, J_{BX}= 12.03 Hz, 1H, C_4-H_B pyrazoline), 5.47 (dd, J_{BX}= 12.06 Hz, J_{AX}= 5.91 Hz, 1H, C_5-H_X pyrazoline), 6.03 (s, 2H), 6.82-6.85 (m, 2H), 6.91-6.96 (m, 2H), 7.01 (d, J = 8.70 Hz, 1H), 7.15-7.21 (m, 2H), 7.32-7.38 (m, 2H), 7.68 (d, J= 5.04 Hz, 1H). ^{13}C NMR (75 MHz, DMSO-d_6) δ / ppm: 44.3 (CH_2), 63.3 (CH), 101.6 (CH_2), 106.5 (CH), 109.1 (CH), 110.3 (C), 113.5 (CH), 115.3 (2CH), 119.4 (d, J= 30.54 Hz, CH), 128.1 (d, J= 28.02 Hz, CH), 129.4 (CH), 131.9 (2CH), 136.3 (d, J= 43.55 Hz, 2C), 143.6 (C), 145.1 (C), 147.1 (C), 148.2 (C). HRMS (*m/z*): $[M+H]^+$ calcd. for $C_{20}H_{15}BrN_2O_2S$: 427.0110. Found: 427.0111.

*1-(4-Methylphenyl)-5-(3,4-methylenedioxyphenyl)-3-(2-thienyl)-4,5-dihydro-1H-pyrazole (**2d**)*[28]

Dark brown powder. M.P.: 152-154 ºC. IR ν_{max} (cm^{-1}): 3107, 3070, 2916, 2860, 1606, 1556, 1514, 1504, 1483, 1442, 1377, 1321, 1311, 1240, 1193, 1130, 1114, 1099, 1037, 995, 939, 898, 854, 817, 804, 721, 702, 665. ^{1}H NMR (300 MHz, DMSO-d_6) δ / ppm: 2.16 (s, 3H), 3.08 (dd, J_{AB}= 17.28 Hz, J_{AX}= 6.54 Hz, 1H, C_4-H_A pyrazoline), 3.84 (dd, J_{BA}= 17.28 Hz, J_{BX}= 12.06 Hz, 1H, C_4-H_B pyrazoline), 5.36 (dd, J_{BX}= 11.97 Hz, J_{AX}= 6.54 Hz, 1H, C_5-H_X pyrazoline), 5.97 (s, 2H), 6.77 (s, 2H), 6.85 (d, J= 8.37 Hz, 2H), 6.95-6.98 (m, 3H), 7.07-7.10 (m, 1H), 7.21-7.22 (m, 1H), 7.58 (d, J= 4.86 Hz, 1H). ^{13}C NMR (75 MHz, DMSO-d_6) δ / ppm: 20.6 (CH_3), 44.1 (CH_2), 63.8 (CH), 101.5 (CH_2), 106.6 (CH), 109.0 (CH), 113.7 (2CH), 119.6 (CH), 123.1 (C), 125.6 (CH), 127.8 (d, J= 19.81 Hz, CH), 128.2 (CH), 129.9 (d, J= 16.17 Hz, 2CH), 136.6 (2C), 142.4 (C), 143.7 (C), 146.9 (C), 148.1 (C). HRMS (*m/z*): $[M+H]^+$ calcd. for $C_{21}H_{18}N_2O_2S$: 363.1162. Found: 363.1167.

*1-(4-Methylsulfonylphenyl)-5-(3,4-methylenedioxyphenyl)-3-(2-thienyl)-4,5-dihydro-1H-pyrazole (**2e**)*[28]

Yellow powder. M.P.: 170-171 ºC. IR ν_{max} (cm^{-1}): 3099, 3001, 2924, 2823, 1589, 1502, 1483, 1442, 1419, 1388, 1315, 1298, 1246, 1139, 1089, 1029, 948, 921, 900, 821, 769, 717. ^{1}H NMR (300 MHz, DMSO-d_6) δ / ppm: 3.07 (s, 3H), 3.19 (dd, J_{AB}= 17.58 Hz, J_{AX}= 5.01 Hz, 1H, C_4-H_A pyrazoline), 3.96 (dd, J_{BA}= 17.61 Hz, J_{BX}= 11.91 Hz, 1H, C_4-H_B pyrazoline), 5.58 (dd, J_{BX}= 11.88 Hz, J_{AX}= 5.01 Hz, 1H, C_5-H_X pyrazoline), 5.99 (d, J= 1.74 Hz, 2H), 6.74-6.79 (m, 2H), 6.88 (d, J= 7.92 Hz, 1H), 7.07 (d, J= 8.88 Hz, 2H), 7.14 (dd, J= 4.98 Hz, J= 3.69 Hz, 1H), 7.36 (d, J= 3.51 Hz, 1H), 7.65-7.69 (m, 3H). ^{13}C NMR (75 MHz, DMSO-d_6) δ / ppm: 44.3 (CH_3), 44.6 (CH_2), 62.6 (CH), 101.6 (CH_2), 106.4 (CH), 109.2 (CH), 112.6 (2CH), 119.4 (CH), 128.5 (CH), 129.1 (2CH), 129.4 (CH), 129.6 (CH), 135.3 (C), 135.6 (2C), 147.3 (3C), 148.3 (C). HRMS (*m/z*): $[M+H]^+$ calcd. for $C_{21}H_{18}N_2O_4S_2$: 427.0781. Found: 427.0781.

*1-(3-Nitrophenyl)-5-(3,4-methylenedioxyphenyl)-3-(2-thienyl)-4,5-dihydro-1H-pyrazole (**2f**)*

Orange powder. M.P.: 179-181 ºC. IR ν_{max} (cm^{-1}): 3113, 2914, 2887, 1612, 1570, 1519, 1498, 1481, 1438, 1379, 1344, 1319, 1242, 1205, 1186, 1111, 1099, 1033, 1008, 966, 929, 887, 856, 848, 827, 804, 786, 734, 709, 663. ^{1}H NMR (300 MHz, DMSO-d_6) δ / ppm: 3.22 (dd, J_{AB}= 17.58 Hz, J_{AX}= 5.58 Hz, 1H, C_4-H_A pyrazoline), 3.96 (dd, J_{BA}= 17.55 Hz, J_{BX}= 11.94 Hz, 1H,

Accepted Manuscript

C_4-H_B pyrazoline), 5.56 (dd, J_{BX}= 11.88 Hz, J_{AX}= 5.70 Hz, 1H, C_5-H_X pyrazoline), 5.99 (d, *J*= 2.46 Hz, 2H), 6.78-6.83 (m, 2H), 6.89 (d, *J*= 7.83 Hz, 1H), 7.14 (dd, *J*= 3.63 Hz, *J* = 5.01 Hz, 1H), 7.25 (dd, *J* = 8.22 Hz and *J* = 2.31 Hz, 1H), 7.35 (d, *J*= 3.60 Hz, 1H), 7.43 (t, *J*= 8.16 Hz, 8.10 Hz, 16.26 Hz, 1H), 7.54 (dd, *J*= 8.04 Hz, *J*= 2.22 Hz, 1H), 7.68 (d, *J*= 5.04 Hz, 1H), 7.76-7.78 (m, 1H). ^{13}C NMR (75 MHz, DMSO-d_6) δ / ppm: 44.4 (CH_2), 63.2 (CH), 101.6 (CH_2), 106.5 (CH), 107.1 (CH), 109.2 (CH), 113.1 (CH), 119.1 (CH), 119.7 (CH), 128.4 (CH), 128.9 (CH), 129.1 (CH), 130.8 (CH), 135.5 (2C), 145.0 (C), 146.6 (C), 147.3 (C), 148.4 (C), 149.0 (C). HRMS (*m/z*): $[M+H]^+$ calcd. for $C_{20}H_{15}N_3O_4S$: 394.0856. Found: 394.0862.

*1-(3-Fluorophenyl)-5-(3,4-methylenedioxyphenyl)-3-(2-thienyl)-4,5-dihydro-1H-pyrazole (**2g**)*

Yellow powder. M.P.: 130-131 ºC. IR ν_{max} (cm^{-1}): 3105, 3072, 2904, 1604, 1571, 1490, 1483, 1442, 1382, 1323, 1269, 1242, 1230, 1186, 1155, 1130, 1112, 1037, 1006, 960, 939, 891, 840, 819, 802, 761, 719, 680, 669. ^{1}H NMR (300 MHz, DMSO-d_6) δ / ppm: 3.14 (dd, J_{AB}= 17.46 Hz, J_{AX}= 5.91 Hz, 1H, C_4-H_A pyrazoline), 3.90 (dd, J_{BA}= 17.46 Hz, J_{BX}= 12.00 Hz, 1H, C_4-H_B pyrazoline), 5.44 (dd, J_{BX}= 11.94 Hz, J_{AX}= 5.88 Hz, 1H, C_5-H_X pyrazoline), 5.98 (s, 2H), 6.47-6.54 (m, 1H), 6.69-6.79 (m, 4H), 6.88 (d, *J*= 7.68 Hz, 1H), 7.10-7.13 (m, 1H), 7.17 (d, *J*= 7.23 Hz, 1H), 7.29 (d, *J*= 3.57 Hz, 1H), 7.63 (d, *J*= 5.04 Hz, 1H). ^{13}C NMR (75 MHz, DMSO-d_6) δ / ppm: 44.3 (CH_2), 63.3 (CH), 99.9 (CH), 100.3 (CH), 101.6 (CH_2), 105.1 (CH), 105.4 (CH), 106.5 (CH), 109.2 (d, *J*= 17.66 Hz, 2CH), 119.6 (CH), 128.4 (d, *J*= 14.67 Hz, 2CH), 131.1 (C), 135.7 (C), 136.1 (C), 145.4 (C), 147.1 (C), 148.3 (C), 161.8 and 164.9 (C). HRMS (*m/z*): $[M+H]^+$ calcd. for $C_{20}H_{15}FN_2O_2S$: 367.0911. Found: 367.0911.

*1-(3-Bromophenyl)-5-(3,4-methylenedioxyphenyl)-3-(2-thienyl)-4,5-dihydro-1H-pyrazole (**2h**)*

Beige powder. M.P.: 125-126 ºC. IR ν_{max} (cm^{-1}): 3107, 3070, 2914, 2872, 1589, 1579, 1556, 1500, 1475, 1444, 1373, 1346, 1317, 1238, 1203, 1184, 1118, 1099, 1078, 1035, 1001, 985, 933, 910, 858, 837, 817, 758, 715, 705, 675. ^{1}H NMR (300 MHz, DMSO-d_6) δ / ppm: 3.14 (dd, J_{AB}= 17.49 Hz, J_{AX}= 5.82 Hz, 1H, C_4-H_A pyrazoline), 3.89 (dd, J_{BA}= 17.52 Hz, J_{BX}= 12.03 Hz, 1H, C_4-H_B pyrazoline), 5.45 (dd, J_{BX}= 11.94 Hz, J_{AX}= 5.82 Hz, 1H, C_5-H_X pyrazoline), 5.98 (s, 2H), 6.75-6.78 (m, 2H), 6.83-6.89 (m, 3H), 7.07-7.15 (m, 3H), 7.30 (dd, *J*= 3.57 Hz, *J*= 0.93 Hz, 1H), 7.64 (dd, *J*= 5.04 Hz, *J*= 0.93 Hz, 1H). ^{13}C NMR (75 MHz, DMSO-d_6) δ / ppm: 44.3 (CH_2), 63.1 (CH), 101.6 (CH_2), 106.5 (CH), 109.1 (CH), 112.2 (CH), 115.6 (CH), 119.6 (CH), 121.4 (CH), 122.7 (C), 128.4 (d, *J*= 7.41 Hz, 2CH), 128.6 (CH), 131.3 (CH), 135.8 (d, *J*= 22.81 Hz, 2C), 145.7 (d, *J*= 5.97 Hz, 2C), 147.1 (C), 148.3 (C). HRMS (*m/z*): $[M+H]^+$ calcd. for $C_{20}H_{15}BrN_2O_2S$: 427.0110. Found: 427.0119.

Accepted Manuscript

IR, ^{1}H AND ^{13}C NMR, HRMS SPECTRA OF COMPOUNDS **2a-h**



Figure S-1. IR spectrum of compound **2a**



Figure S-2. ^{1}H NMR spectrum of compound **2a**

Accepted Manuscript



Figure S-3. ^{13}C NMR spectrum of compound **2a**



Rank	Score	Formula (M)	Ion	Meas. m/z	Pred. m/z	Df. (mDa)	Df. (ppm)	Iso	DBE
1	0.00	C21 H15 N3 O2 S	[M+H]+	374.0964	374.0958	0.6	1.60	0.00	16.0

Figure S-4. HRMS spectrum of compound **2a**

Accepted Manuscript



Figure S-5. IR spectrum of compound **2b**



Figure S-6. ^{1}H NMR spectrum of compound **2b**

Accepted Manuscript



Figure S-7. ^{13}C NMR spectrum of compound **2b**



Rank	Score	Formula (M)	Ion	Meas. m/z	Pred. m/z	Df. (mDa)	Df. (ppm)	Iso	DBE
1	51.54	C20 H15 N2 O2 F S	[M+H]+	367.0917	367.0911	0.6	1.63	52.37	14.0

Figure S-8. HRMS spectrum of compound **2b**

Accepted Manuscript



Figure S-9. IR spectrum of compound **2c**



Figure S-10. ^{1}H NMR spectrum of compound **2c**

Accepted Manuscript



Figure S-11. ^{13}C NMR spectrum of compound **2c**



Rank	Score	Formula (M)	Ion	Meas. m/z	Pred. m/z	Df. (mDa)	Df. (ppm)	Iso	DBE
1	11.31	C20 H15 N2 O2 S Br	[M+H]+	427.0111	427.0110	0.1	0.23	11.31	14.0

Figure S-12. HRMS spectrum of compound **2c**

Accepted Manuscript



Figure S-13. IR spectrum of compound **2d**



Figure S-14. ^{1}H NMR spectrum of compound **2d**

Accepted Manuscript



Figure S-15. ^{13}C NMR spectrum of compound **2d**



Figure S-16. HRMS spectrum of compound **2d**

Accepted Manuscript



Figure S-17. IR spectrum of compound **2e**



Figure S-18. ^{1}H NMR spectrum of compound **2e**

Accepted Manuscript



Figure S-19. ^{13}C NMR spectrum of compound **2e**



Rank	Score	Formula (M)	Ion	Meas. m/z	Pred. m/z	Df. (mDa)	Df. (ppm)	Iso	DBE
1	85.15	C21 H18 N2 O4 S2	[M+H]+	427.0781	427.0781	0.0	0.00	85.15	14.0

Figure S-20. HRMS spectrum of compound **2e**

Accepted Manuscript



Figure S-21. IR spectrum of compound **2f**



Figure S-22. ^{1}H NMR spectrum of compound **2f**

Accepted Manuscript



Figure S-23. ^{13}C NMR spectrum of compound **2f**



Rank	Score	Formula (M)	Ion	Meas. m/z	Pred. m/z	Df. (mDa)	Df. (ppm)	Iso	DBE
1	0.00	C20 H15 N3 O4 S	[M+H]+	394.0862	394.0856	0.6	1.52	0.00	15.0

Figure S-24. HRMS spectrum of compound **2f**

Accepted Manuscript



Figure S-25. IR spectrum of compound **2g**



Figure S-26. ^{1}H NMR spectrum of compound **2g**

Accepted Manuscript



Figure S-27. ^{13}C NMR spectrum of compound **2g**



Figure S-28. HRMS spectrum of compound **2g**

Accepted Manuscript



Figure S-29. IR spectrum of compound **2h**



Figure S-30. ^{1}H NMR spectrum of compound **2h**

Accepted Manuscript



Figure S-31. ^{13}C NMR spectrum of compound **2h**



Figure S-32. HRMS spectrum of compound **2h**

Accepted Manuscript